• Pediatric obesity drug development faces sustained demand, with roughly 200 obesity assets globally potentially triggering pediatric study requirements if successfully developed for adults.
• Without sustained intervention, approximately 746 million children and adolescents could be overweight or obese by 2050, expanding long-term treatment needs.
• Fewer than 1% of eligible US adolescents received an FDA-approved obesity medicine in 2023, highlighting a substantial access gap.
• Tirzepatide’s SURMOUNT-ADOLESCENTS-2 obesity trial targets primary completion in October 2026, offering the nearest major pediatric obesity data readout.
• Semaglutide’s STEP-Young trial covers ages 6-18, with primary completion expected around 2027, potentially supporting expansion into children younger than 12.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Signant Health published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.